### HUMAN CANCER BIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5580</td>
<td>Integrative Genomics Analysis Identifies Candidate Drivers at 3q26-29 Amplicon in Squamous Cell Carcinoma of the Lung</td>
<td>Jing Wang, Jun Qian, Megan D. Hoeksema, Yong Zou, Allan V. Espinosa, S.M. Jamsheedur Rahman, Bing Zhang, and Pierre P. Massion</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>5626</td>
<td>Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs</td>
<td>Bertrand Allard, Sandra Pommey, Mark J. Smyth, and John Stagg</td>
</tr>
<tr>
<td>5636</td>
<td>Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells</td>
<td>Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark J. Smyth, Michael H. Kershaw, and Phillip K. Darcy</td>
</tr>
</tbody>
</table>

### Special Features

- **Editorial**
  - 5545 | Announcing the AACR Cancer Progress Report 2013 | Jesse Potash and Kenneth C. Anderson |

- **CCR Translations**
  - 5546 | Better Performance of CARs Deprived of the PD-1 Brake | Aizea Morales-Kastresana, Sara Labiano, José I. Quetglas, and Ignacio Melero |
  - 5549 | Coamplification and Cooperation: Toward Identifying Biologically Relevant Oncogenes | Guochang Huang and Bhuvanesh Singh |

- **CCR Drug Updates**
  - 5552 | Pertuzumab: Optimizing HER2 Blockade | Otto Metzger-Filho, Eric P. Winer, and Ian Krop |

- **Molecular Pathways**
  - 5557 | Human Leukocyte Antigen G (HLA-G) | Giuseppe Curigliano, Carmen Criscitiello, Lucia Gelao, and Aron Goldhirsch |
  - 5564 | Molecular Pathways: Human Leukocyte Antigen G (HLA-G) | Giuseppe Curigliano, Carmen Criscitiello, Lucia Gelao, and Aron Goldhirsch |
  
- **Review**
  - 5572 | The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer | Wen Wee Ma and Manuel Hidalgo |
### Identification of Lethal microRNAs Specific for Head and Neck Cancer
Marlon Lindenbergh-van der Plas, Sanne R. Martens-de Kemp, Michel de Maaker, Wessel N. van Wieringen, Bauke Ylstra, Reuven Agami, Francesco Cerisoli, C. René Leemans, Boudewijn J.M. Braakhuis, and Ruud H. Brakenhoff

### Pharmacologic Inhibition of Jak2−Stat5 Signaling By Jak2 Inhibitor AZD1480 Potently Suppresses Growth of Both Primary and Castrate-Resistant Prostate Cancer
Lei Gu, Zhiyong Liao, David T. Hoang, Ayush Dagvadorj, Shilpa Gupta, Shauna Blackmon, Elyse Ellsworth, Pooja Talati, Benjamin Leiby, Michael Zinda, Costas D. Lallas, Edward J. Trubulski, Peter McCue, Leonard Gomella, Dennis Huszar, and Marja T. Nevalainen

### CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
Melinda Burgess, Devinder Gill, Richa Singhania, Catherine Cheung, Lynne Chambers, Brent A. Benyolds, Louise Smith, Peter Mollee, Nicholas Saunders, and Nigel AJ McMillan

### RG7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response
Xuefeng Yin, Leopoldo Luistro, Hua Zhong, Melissa Smith, Tom Nevins, Kathleen Schostack, Holly Hilton, Tai-An Lin, Theresa Truitt, Denise Biondi, Xiaoqian Wang, Kathryn Packman, Jim Rosinski, Windy Berkofsky-Fessler, Jian-Ping Tang, Saumya Pant, David Geho, Suzana Vega-Harring, Mark DeMario, Hy Levitsky, and Mary Simcox

### REM (Risk of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy
Roberto Angioli, Stella Capriglione, Alessia Aloisi, Daniela Luvero, Ester Valentia Caia, Nella Dugo, Roberto Monterra, Carlo De Cicco Nardone, Corrado Terranova, and Francesco Plotti

### The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas

### The G-Protein–Coupled Receptor CLR Is Upregulated in an Autocrine Loop with Adrenomedullin in Clear Cell Renal Cell Carcinoma and Associated with Poor Prognosis
Leonid L. Nikitenko, Russell Leek, Stephen Henderson, Nischalan Pillay, Helen Turley, Daniele Generali, Sarah Gunnigham, Helen R. Morrin, Andrea Pellagatti, Margaret C.P. Rees, Adrian L. Harris, and Stephen B. Fox

### Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAF<sup>V600E</sup>-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Emanuela Romano, Sylvain Pradervand, Alexandra Paillussos, Johann Weber, Keith Harshman, Katja Muelelethal, Daniel Speiser, Solange Peters, Donata Rimoldi, and Olivier Michieli
Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity
Sarah McWhinney-Glass, Stacey J. Winham, Daniel L. Hertz, Jane Yen Revollo, Jim Paul, Yijing He, Robert Brown, Alison A. Motisngier-Reif, and Howard L. McLeod; For the Scottish Gynaecological Clinical Trials Group

Association of TP53 Mutational Status and Gender with Survival after Adjuvant Treatment for Stage III Colon Cancer: Results of CALGB 89803

Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer

Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER
The cover shows a section from the prostate of a patient with Gleason sum 7 prostate cancer. Duolink proximity ligation assay in the section shows strong interaction between AR and AKR1C3 (red). Nucleus was counterstained with DAPI and imaged using a fluorescent microscope. For details, see the article by Yepuru and colleagues on page 5613 of this issue.